Document is current
Any future updates will be listed below
-
Authors
Der-Avakian, Andre
Barnes, Samuel A.
Lees, Ty https://orcid.org/0000-0002-7321-2704
Schroder, Hans S.
Kangas, Brian D. https://orcid.org/0000-0002-4597-9801
Linton, Samantha R. https://orcid.org/0000-0001-7512-1585
Nickels, Stefanie https://orcid.org/0000-0003-3788-2919
Robble, Mykel A.
Breiger, Micah
Iturra-Mena, Ann M.
Lobien, Rachel
Perlo, Sarah
Cárdenas, Emilia F.
Nowicki, Genevieve P.
Wu, Zeyun
Pan, Hongyi
Dillon, Daniel G. https://orcid.org/0000-0002-1977-700X
Kesby, James P. https://orcid.org/0000-0002-5814-8062
Bergman, Jack
Carlezon, William A. Jr
Risbrough, Victoria B.
Mukamel, Eran https://orcid.org/0000-0003-3203-9535
Leutgeb, Stefan https://orcid.org/0000-0003-3367-6536
Pizzagalli, Diego A. https://orcid.org/0000-0002-7772-1143
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (UH2 MH109334, UH3 MH109334)
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 14 August 2025
First Online: 23 August 2025
Competing interests
: Over the past 3 years, B.D.K. has had sponsored research agreements with BlackThorn Therapeutics, Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, and Takeda Pharmaceuticals. Over the past 3 years, V.B.R. has received consulting fees from Engrail Pharmaceuticals, Jazz Pharmaceuticals, and Cohen Veterans Biosciences. Over the past 3 years, D.A.P. has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Neuroscience Software, and Takeda; he has received honoraria from the American Psychological Society, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, DARPA, Millennium Pharmaceuticals, the National Institute of Mental Health, and Wellcome Leap; he has received stock options from Ceretype Neuromedicine, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. No funding or any involvement from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures.
